←
Nasim Wiegley, MD, FASN1,370 posts
Nasim Wiegley, MD, FASN avatar

Nasim Wiegley, MD, FASN

@NWiegley

Fellowship Director @UCDNephrology | Glomerular Disease Specialist | Director GN Clinic | @GlomCon Faculty and Editor | tweets=my own

◷ Joined April 2018▧ 117 Photos and videos
UC Davis Nephrology avatar
⟳ Nasim Wiegley, MD, FASN retweeted
UC Davis Nephrology@UCDNephrology·Oct 25

🎉 Last day of posters, and UC Davis Nephrology showed up strong! 💙💛 Huge shoutout to our fellows and faculty for sharing their work, presenting interesting cases, original research & representing our division with pride at #KidneyWk 2026. Couldn’t be prouder of this team! 👏

Post attachmentPost attachmentPost attachmentPost attachment
UC Davis Nephrology avatar
⟳ Nasim Wiegley, MD, FASN retweeted
UC Davis Nephrology@UCDNephrology·Oct 25

💙💛 Wrapping up #KidneyWk 2026 with our UC Davis Nephrology crew! Grateful for a wonderful week of learning, reconnecting with colleagues, and celebrating the kidney community. So proud of our team and all the memories we made. Until next year! 🎉

Post attachmentPost attachmentPost attachment
NEJM avatar
⟳ Nasim Wiegley, MD, FASN retweeted
NEJM@NEJM·Oct 23

Presented at #KidneyWk: Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo. Full phase 3 RAINIER AIS-D08 trial results: nej.md/3VWcGh6 @ASNKidney

Post attachment
NEJM avatar
⟳ Nasim Wiegley, MD, FASN retweeted
NEJM@NEJM·Oct 22

Presented at #KidneyWk: In patients with IgA nephropathy, atacicept, a human TACI–Fc fusion protein that modulates B-cell activity, slowed and stabilized the decline in the eGFR as compared with placebo. Full phase 3 ORIGIN 3 trial results: nej.md/4dJYTAo @ASNKidney

Post attachment
NEJM avatar
⟳ Nasim Wiegley, MD, FASN retweeted
NEJM@NEJM·Oct 23

Presented at #KidneyWk: An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo. Full I CAN trial results: nej.md/4iwTFdS @ASNKidney

Post attachment
Int Society of Nephrology avatar
⟳ Nasim Wiegley, MD, FASN retweeted
Int Society of Nephrology@ISNkidneycare·Oct 24

📣 A special invitation from ISN President-Elect @kidneydoc101! Join us at #ISNWCN in Kuala Lumpur, Malaysia, on April 1-4, 2027 and be part of the global kidney community coming together to advance kidney health worldwide. 🌏 We look forward to seeing you there! 🇲🇾

0:22
ASN Publications avatar
⟳ Nasim Wiegley, MD, FASN retweeted
ASN Publications@asnpublications·Aug 6

APOL1 risk variants (G1/G2) form membrane pores that increase Ca²⁺ influx and kidney cell damage. The APOL1 inhibitor VX-147 and the M1 (N264K) variant reduced Ca²⁺ entry and improved cell survival, highlighting potential therapies for APOL1 kidney disease. #ASNJASN kidney.pub/JASN1159?utm_sour…

Post attachment